Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Camrelizumab + SOX + radiotherapy
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Camrelizumab + SOX + radiotherapy is a combination therapy used primarily in the treatment of advanced or locally advanced gastric cancer, gastroesophageal junction cancer, and esophageal cancer. Camrelizumab is a humanized monoclonal antibody that targets programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. The SOX regimen consists of S-1 (an oral fluoropyrimidine derivative) and oxaliplatin (a platinum-based chemotherapeutic agent), both of which inhibit DNA synthesis and cell division in tumor cells. Radiotherapy uses ionizing radiation to damage the DNA of cancer cells directly. This combination aims to maximize anti-tumor efficacy by integrating immunotherapy with chemotherapy and local tumor control via radiation[3][4][5][6]. Camrelizumab was developed by Jiangsu Hengrui Medicine.
- Brand names
- AiRuiKa
- Other names
- S-1 plus oxaliplatin plus radiotherapyS1 plus oxaliplatin plus radiotherapyS 1 plus oxaliplatin plus radiotherapycamrelizumab plus S-1 and oxaliplatin and radiotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on Camrelizumab + SOX + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Camrelizumab + SOX + radiotherapy.